<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="therapeutic drugs against the COVID-19. However, until now, no promising" exact="treatment" post="options, as well as vaccines, are available. In this"/>
 <result pre="cell membrane. â€¢CRISPR-Cas12, ddPCR and RT-LAMP methods may improve the" exact="detection" post="of SARS-CoV-2. â€¢Active hexose correlated compound (AHCC), an immune-stimulant"/>
 <result pre="with atypical clinical symptoms, resulting in either misdiagnosis or missed" exact="diagnosis" post="(Zhou and Liu, 2020). These might be among the"/>
 <result pre="contact with respiratory droplets of infected individuals. The time from" exact="infection" post="to the manifestation of symptoms ranges from 2 to"/>
 <result pre="the manifestations including headache and nausea in response to COVID-19" exact="infection" post="suggest the effect of SARS-CoV-2 on the neurological system."/>
 <result pre="constitute 31% of their virome. They are immune to viral" exact="infection" post="and the characteristics such as higher species diversity (over"/>
 <result pre="in severe cases, suggesting that the primary target of COVID-19" exact="infection" post="is T lymphocytes (Qin et al., 2020). Similarly, Shi"/>
 <result pre="group O are comparatively at lower risk for contracting COVID-19" exact="infection" post="(Zhao et al., 2020). Although it is very early"/>
 <result pre="patients. 4 Therapeutic options The overall risks associated with COVID-19" exact="infection" post="can be mitigated with effective eradication of the infection."/>
 <result pre="mitigated with effective eradication of the infection. Currently, no promising" exact="treatment" post="options are available against COVID19 that can be recommended"/>
 <result pre="combination with chloroquine or interferon beta showed effectiveness against COVID-19" exact="infection" post="(Sheahan et al., 2020). In addition, W.H.O and C.D.C"/>
 <result pre="have developed a tool, namely Deep Docking for the computer-based" exact="screening" post="of a large number of molecules in a very"/>
 <result pre="Since no specific antiviral agents are available, therefore, the provided" exact="treatment" post="options to COVID-19 patients are all supportive in nature."/>
 <result pre="to COVID-19 patients are all supportive in nature. Besides effective" exact="treatment" post="options and preventive strategies must be developed and practiced"/>
 <result pre="Chinese medicines, which have been found effective against the COVID-19" exact="infection" post="(Chan et al., 2020). Previous studies have shown that"/>
 <result pre="(Xia et al., 2020). However, any conclusion to associate COVID-19" exact="infection" post="with cancer should be drawn carefully, as no convincing"/>
 <result pre="Therefore, diabetic patients seem to be more susceptible to COVID-19" exact="infection" post="than others. Yang et al., (!!! INVALID CITATION (Yang"/>
 <result pre="increase the expression of ACE2. Consequently, this would facilitate the" exact="infection" post="with SARS-CoV-2, which uses this protein as an entry"/>
 <result pre="and thus makes these tissues and organs susceptible to COVID-19" exact="infection" post="and damage to multiple organs (Liu et al., 2020;"/>
 <result pre="have an increased risk of developing severe conditions, while, COVID-19" exact="infection" post="can exacerbate the damage of the heart. In COVID-19"/>
 <result pre="methods For patients who meet specified criteria, in addition to" exact="testing" post="for other respiratory pathogens, the CDC recommends collection of"/>
 <result pre="provided detailed descriptions of approved methods being used for coronavirus" exact="detection" post="(WHO, 2020), which is based on the detection of"/>
 <result pre="for coronavirus detection (WHO, 2020), which is based on the" exact="detection" post="of unique sequences of viral RNA. In routine-based testing"/>
 <result pre="the detection of unique sequences of viral RNA. In routine-based" exact="testing" post="for COVID-19 patients, the presence of SARS-COV-2 is determined"/>
 <result pre="COVID-19 patients, the presence of SARS-COV-2 is determined through the" exact="detection" post="of viral genes namely N, E, S, and RdRP"/>
 <result pre="viral genes namely N, E, S, and RdRP using real-time" exact="polymerase chain reaction" post="(RT-PCR). Moreover, the RNA-sequencing technique is also employed for"/>
 <result pre="swab of patients may give false-negative results during RT- PCR-based" exact="detection" post="(Lucia et al., 2020). Besides PCR-based methods, researchers and"/>
 <result pre="instance, a CRISPR-Cas12-based method has been developed with an estimated" exact="detection" post="limit of 10 copies/Î¼L (Lucia et al., 2020). Another"/>
 <result pre="(ddPCR) has recently been developed to detect SARS-CoV-2 with a" exact="detection" post="efficiency of at least 500 times higher than RT-PCR"/>
 <result pre="cost-effective technique is still required to be developed so that" exact="testing" post="procedures could become easy in low income and hardest"/>
 <result pre="further investigations and experiments are necessary to reach an effective" exact="treatment" post="strategy. Active hexose correlated compound (AHCC) is an Î±-glucan-based"/>
 <result pre="nano architectural electrochemical immunosensors that can be utilized for the" exact="detection" post="of pathogenic viral organisms. Electrochemistry guided immunosensors have become"/>
 <result pre="The need for a faster sensing process at a lower" exact="detection" post="limit is an important but challenging strategy. Designing novel"/>
 <result pre="composite assays can be developed from disposable electrodes for multi" exact="detection" post="purposes. 9 Conclusion The deadly and highly infectious COVID-19"/>
 <result pre="larger than reported figures due to the lack of high" exact="testing" post="capacity in some countries, accurate data recording systems in"/>
 <result pre="may get worsened in the near future if not effective" exact="treatment" post="or vaccine is developed to combat or prevent the"/>
 <result pre="J. Med.3821820201708172010.1056/NEJMoa200203232109013 HanJ.-H.LeeD.ChewC.H.C.KimT.PakJ.J.A multi-virus detectable microfluidic electrochemical immunosensor for simultaneous" exact="detection" post="of H1N1, H5N1, and H7N9 virus using ZnO nanorods"/>
 <result pre="ShiY.TanM.ChenX.LiuY.HuangJ.OuJ.DengX.Immunopathological Characteristics of Coronavirus Disease 2019 Cases in Guangzhou2020medRxivChina10.1101/03.12.200347362020 SinghR.HongS.JangJ.Label-free" exact="detection" post="of influenza viruses using a reduced graphene oxide-based electrochemical"/>
 <result pre="billion compoundsMol Inform3982020e200002810.1002/minf.20200002832162456 WangM.FuA.HuB.TongY.LiuR.GuJ.LiuJ.JiangW.ShenG.ZhaoW.MenD.YuL.DengZ.LiY.LiuT.Nanopore target sequencing for accurate and comprehensive" exact="detection" post="of SARS-CoV-2 and other respiratory virusesmedRxiv2020200295382003.2004 WHOLaboratory testing for"/>
 <result pre="and comprehensive detection of SARS-CoV-2 and other respiratory virusesmedRxiv2020200295382003.2004 WHOLaboratory" exact="testing" post="for 2019 novel coronavirus (2019-nCoV) in suspected human casesWHO/COVID-19/laboratory/2020.42020"/>
 <result pre="outbreak of 2019 novel coronavirus disease (COVID-19)]Zhonghua Zhongliu Zazhi422020E006 YangW.DangX.WangQ.XuM.ZhaoQ.ZhouY.ZhaoH.WangL.XuY.WangJ.HanS.WangM.PeiF.WangY.Rapid" exact="detection" post="of SARS-CoV-2 using reverse transcription RT-LAMP methodmedRxiv202010.1101/03.02.200301302020 ZamanW.SaqibS.UllahF.AyazA.YeJ.COVID-19: phylogenetic"/>
 <result pre="between the ABO Blood Group and the COVID-19 SusceptibilitymedRxiv202010.1101/03.11.200310962020 ZhouL.LiuH.G.[Early" exact="detection" post="and disease assessment of patients with novel coronavirus pneumonia]Zhonghua"/>
</results>
